New Experimental Modalities in the Control of Neoplasia

Acquisition of new knowledge about the biological and bio­ chemical nature of neoplastic cells has led to the design and development of several experimental approaches in the tre&tment of cancer. These approaches emerge from the recent work in tu­ mor virology, e. g. the control of vital cellular genes by viral regulatory signals; the implication of monoclonal antibodies as a vehicle for the targeted drug delivery and selective de­ struction of tumor cells; immunologic advances in the recog­ nition of some specific events during metastatic growth; the role of biological response modifiers in modifying or rever­ sing malignant growth; and biochemical advances, such as the role of gene amplification in drug resistance and the app­ roaches to the reversal of resistance in drug refractory cancer, the role of membranes in designing useful strategies, the identification of new enzymic targets in some types of cancer cells, and the characterization of metabolically active forms of cytostatic compounds. These are the important issues which were addressed in an international NATO Advanced Study Institute (ASI) attended by scientists from allover the world representing a wide spectrum of scientific disciplines. Although the acquired immune deficiency syndrome (AIDS) is not a malignant disease, but the etiological involvement of a retrovirus belonging to the family of human T-cell lympho­ tropic viruses which cause leukemia and lymphomas in man, justifies its inclusion in the agenda of this Study Institute. Scientific presentations from Drs.

Inhalt

1. A Developmental Biologist's View of Cancer.- 2. Oncogenes in Development, Neoplasia and Evolution.- 3. Acquisition of Metastatic Properties via Somatic Cell Fusion: Implications for Tumor Progression in vivo.- 4. Oncogenes and Tyrosine Kinase Activities as a Function of the Metastatic Phenotype.- 5. Immune Reactivities During the Precancer and Early Cancer Periods: Novel Approaches for Immunomodulation.- 6. Immunomodulation of Tumor Metastases.- 7. Monoclonal Antibody Targeting of Anti-Cancer Agents.- 8. Treatment of Human B Cell Lymphoma with Monoclonal Anti-Idiotype Antiboaies.- 9. Human Monoclonal Antibodies Directed Against HuMTV Antigens form Human Breast Cancer Cells.- 10. Recent Advances in Thymic Hormone Research.- 11. T-Cell Growth Factor (Interleukin -2).- 12. Drug Resistance: New Approaches to Treatment.- 13. Mechanisms of Membrane-Mediated Cytotoxicity by Adriamycin.- 14. Terminal Transferase and Adenosine Deaminase Activities in Human Neoplasia: Their Role in Modulating Cancer Treatment.- 15. Inhibitors of Terminal Transerase: A New Strategy for the Treatment of Human Leukemia.- 16. DNA-Protein Crosslinking of Platinum Coordination Complex in Living Cells: Implication to Evaluate the Cytotoxic Effects of Chemotherapeutic Agents.- 17. Antitumor Activity, Pharmacology and Clinical Trials of Elliptinium (NSC 264-137).- 18. Therapeutic Efficacy of Oxazaphosphorines by Immunomodulation.- 19. The Role of Cellular Glutathione in Protecting Mammalian Cells from X Radiation and Chemotherapy Agents in vitro.- 20. The Role of Papilloma Viruses in Human Cancer.- 21 Anti-Viral Vaccine Control of EB Virus-Associated Cancers.- 22. Bovine Leukosis Virus as a Model for Human Retroviruses.- 23. Human T-Lymphotropic Retroviruses and their Role in Human Diseases.- 24. Molecular Biology of the Human T-Lymphotropic Retroviruses.- 25. Antiviral Approaches in the Treatment of Acquired Immune Deficiency Syndrome.- 26. Inhibition of HTLV-III Replication in Cell Cultures.- 27. Proteins Encoded by the Human T-Lymphotropic Virus Type III/Lymphadenopathy Associated Virus (HTLV-III/LAV) Genes.- 28. Cytopathogenic Mechanisms which Lead to Cell Death of HTLV-III Infected T. Cells.- 29. Clinical Aspects of Thymic Factors in the Treatment of Immunodeficiency Diseases and Neoplasia: Achievements and Failures.- 30. An Overview of the Current Understanding and Management of the Non-Hodgkin's Lymphomas.- Participants.